• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioDelivery Sciences International

BioDelivery Sciences, Teva settle patent fight over opioid dependence treatment

October 12, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences (NSDQ:BDSI) said today that it inked a deal with Teva Pharmaceuticals (NYSE:TEVA) to settle claims that the generic form of BioDelivery Sciences’ Bunavail buccal film that Teva is trying to bring to market in the U.S. infringes upon several patents owned by the Raleigh, N.C.-based company. As part of the deal, which was reached in […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: BioDelivery Sciences International, Teva Pharmaceuticals

BioDelivery Sciences president, CEO Sirgo to retire | Personnel Moves – Aug 29, 2017

August 29, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences (NSDQ:BDSI) said last week that its president & CEO, Mark Sirgo, plans to retire at the end of this year. Sirgo has held the corner office at the Raleigh, N.C.-based company since 2005. He will stay on as vice chairman of the board and will help determine his successor, BioDelivery Sciences reported. “After thirteen […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, BioDelivery Sciences International, Insulet, Merrimack Pharmaceuticals, Novartis, Ocular Therapeutix, pierispharmaceuticals, Proteus Digital Health, Shire, SteadyMed Therapeutics

BioDelivery Sciences beats Q2 rev estimates, misses on EPS

August 10, 2017 By Sarah Faulkner

BioDelivery Sciences International

Shares in BioDelivery Sciences International (NSDQ:BDSI) fell today after the pharmaceutical company beat sales estimates but missed earnings expectations on Wall Street with its second quarter results. The Raleigh, N.C.-based company posted a net loss of -$14.9 million on sales of $8.7 million for the 3 months ended June 30, paring losses by 9.7% on sales […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Sublingual films, Wall Street Beat Tagged With: BioDelivery Sciences International

BioDelivery Sciences, Purdue ink exclusive distribution deal for Belbuca in Canada

July 12, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that it inked an exclusive distribution deal with Purdue Pharma‘s Canada branch for the licensing, distribution, marketing and sale of Belbuca in Canada. The company’s Belbuca buccal film was designed to deliver buprenorphine for patients with chronic pain. It was cleared by Health Canada in June for patients with pain severe […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: BioDelivery Sciences International, purduepharma

BioDelivery wins Health Canada approval for Belbuca pain relief product

June 23, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that Health Canada approved its buprenorphine hydrochloride buccal film, Belbuca, for the management of pain severe enough to necessitate daily, long-term opioid treatment and for which alternative management options are inadequate. The company said it plans to commercialize Belbuca in Canada through an unnamed partner and that the launch […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: BioDelivery Sciences International

BioDelivery Sciences brings novel drug delivery tech to pain management, opioid addiction

June 20, 2017 By Sarah Faulkner

BioDelivery Sciences International

As the American public grapples with an ongoing opioid crisis, pain management companies are looking for ways to innovate their products in an attempt to avoid potential abuse. For years, BioDelivery Sciences International (NSDQ:BDSI) has developed mucoadhesive buccal films loaded with painkillers for pain management and addiction therapy. Now it is developing a buprenorphine depot […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: BioDelivery Sciences International

FDA OKs BioDelivery Sciences’ Bunavail opioid dependence film

May 2, 2017 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that the FDA approved a supplemental new drug application for its Bunavail buprenorphine and naloxone buccal film. The revised indication allows patients to use the product to initiate buprenorphine treatment for opioid dependence. Induction is the initial process by which a patient transitions from abusing an opioid to buprenorphine […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: BioDelivery Sciences International

Endo cuts staff in restructuring effort

January 26, 2017 By Sarah Faulkner

Endo Pharmaceuticals

Endo International (NSDQ:ENDP) said today that it will cut 90 full-time positions from its workforce in an effort to restructure its generics and U.S. branded pharmaceutical businesses. The company said it will invest part of the cost savings that result from its restructuring into Endo’s core products and new product development. “Last year, Endo completed […]

Filed Under: Pharmaceuticals, Wall Street Beat Tagged With: BioDelivery Sciences International, Endo Pharmaceuticals

BioDelivery names Ginsberg as biz dev veep | Personnel Moves, Dec. 14, 2016

December 14, 2016 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that it named Peter Ginsberg as its VP of business development. Prior to joining the Raleigh, N.C.-based company, Ginsberg led business development at United Therapeutics and directed a $350 million sale of the company’s priority review voucher. He has also served as VP of business & technology development for […]

Filed Under: Featured, Pain Management, Personnel, Pharmaceuticals Tagged With: BioDelivery Sciences International

BioDelivery’s topical gel for diabetic neuropathy fails in phase IIb trial

December 13, 2016 By Sarah Faulkner

BioDelivery Sciences International

BioDelivery Sciences International (NSDQ:BDSI) said today that its clonidine topical gel for pain relief in patients with diabetic neuropathy failed in a phase IIb clinical trial. Raleigh, N.C.-based BioDelivery will halt any further development of the painkiller. In the phase IIb clinical trial, BioDelivery’s topical gel did not demonstrate a statistically significant difference in pain relief […]

Filed Under: Clinical Trials, Diabetes, Featured, Pain Management, Wall Street Beat Tagged With: BioDelivery Sciences International, Endo Pharmaceuticals

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS